Alembic Pharmaceuticals Limited has announced the approval of its unaudited financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these results during a meeting held on November 4, 2025. The meeting commenced at 12:00 Noon and concluded at 2:25 p.m.
Financial Performance Highlights
Alembic Pharmaceuticals reported a revenue from operations of ₹1,910.15 crore for Q2 2025, compared to ₹1,647.98 crore in Q2 2024. The total income for the quarter was ₹1,917.06 crore. For the half-year ended September 30, 2025, the revenue from operations stood at ₹3,620.87 crore. The company’s profit before tax for Q2 2025 was ₹223.72 crore.
Balance Sheet Update
As of September 30, 2025, Alembic Pharmaceuticals’ total equity amounted to ₹5,316.01 crore. The non-current liabilities totaled ₹306.89 crore, and current liabilities were ₹1,374.02 crore.
Earnings Per Share
The basic and diluted earnings per share for the quarter ended September 30, 2025, was reported as ₹9.40 per share.
Key Financial Ratios
The debt-equity ratio is 0.27. The debt service coverage ratio is 10.23, and the interest service coverage ratio is also 10.23. The net worth of the company is ₹5,322.35 crore.
Additional Information
The results have been reviewed by the statutory auditors and approved by the Audit Committee and Board of Directors.
Source: BSE
